Loading...
XSHE002099
Market cap1.06bUSD
Jan 14, Last price  
4.93CNY
1D
2.71%
1Q
-16.16%
Jan 2017
-41.86%
IPO
80.92%
Name

Zhejiang Hisoar Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002099 chart
P/E
—
P/S
3.58
EPS
—
Div Yield, %
1.53%
Shrs. gr., 5y
0.29%
Rev. gr., 5y
-4.39%
Revenues
2.17b
-19.68%
506,100,523690,764,236770,205,8801,034,886,0221,062,995,967893,369,0471,074,589,2591,298,437,7631,145,374,3771,160,690,6971,319,135,7372,464,495,5332,433,862,0712,308,922,1702,718,608,7962,941,412,7702,471,386,6262,484,828,4372,704,144,0462,171,886,869
Net income
0k
-100.00%
35,134,10049,596,01552,112,94931,050,88225,597,25330,301,75885,628,270105,064,38622,780,419053,519,259516,587,190225,018,251342,217,155605,003,820770,782,185319,715,24695,229,60088,013,7290
CFO
241m
+107.19%
42,360,66136,071,82361,882,54451,140,58830,607,75998,380,566180,879,96592,619,740180,727,34160,850,636191,561,807462,163,337629,417,200102,676,414791,449,237612,399,095533,869,722102,360,758116,092,038240,536,591
Dividend
May 24, 20230.05 CNY/sh
Earnings
May 20, 2025

Profile

Zhejiang Hisoar Pharmaceutical Co., Ltd., a pharmaceutical company, produces and sells fine chemicals and special raw drugs in China and internationally. It offers antibiotic, anti-virus, cardiovascular, sugar-reducing, and other materials; and medicine intermediates, and other customized and processed products, such as clindamycin, 4-AA Iso-carbapenem series, thiamphenicol, florfenicol, voglibose, eclindamycin, 4-AA iso-carbapenem, thiamphenicol, florfenicol, voglibose, etc. It also exports its products. The company was founded in 1966 and is based in Taizhou, China.
URL
https://www.hisoar.com/
IPO date
Dec 26, 2006
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,171,887
-19.68%
2,704,144
8.83%
Cost of revenue
2,228,858
2,258,380
Unusual Expense (Income)
NOPBT
(56,971)
445,764
NOPBT Margin
16.48%
Operating Taxes
(44,642)
14,725
Tax Rate
3.30%
NOPAT
(12,329)
431,039
Net income
88,014
-7.58%
Dividends
(118,939)
(161,872)
Dividend yield
1.03%
1.43%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,028,833
838,304
Long-term debt
20,420
176,163
Deferred revenue
54,445
Other long-term liabilities
59,992
1,333
Net debt
(1,042,991)
(1,205,041)
Cash flow
Cash from operating activities
240,537
116,092
CAPEX
(153,077)
Cash from investing activities
(128,215)
Cash from financing activities
99,070
FCF
224,152
133,427
Balance
Cash
1,420,571
1,490,816
Long term investments
671,673
728,693
Excess cash
1,983,649
2,084,302
Stockholders' equity
2,710,168
3,216,426
Invested Capital
4,717,106
5,053,381
ROIC
8.78%
ROCE
6.16%
EV
Common stock shares outstanding
1,615,599
1,618,715
Price
7.18
2.43%
7.01
-14.93%
Market cap
11,600,004
2.23%
11,347,194
-14.93%
EV
10,552,381
10,142,153
EBITDA
307,626
782,283
EV/EBITDA
34.30
12.96
Interest
39,616
36,547
Interest/NOPBT
8.20%